Albany Molecular Research (AMRI) Tops Q3 EPS by 2c; Bumps Outlook
Tweet Send to a Friend
Albany Molecular Research (NASDAQ: AMRI) reported Q3 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
